Vanguard Global Advisers
APLS

Vanguard Global Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Vanguard Global Advisers’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,745
Closed -$1.64M – 3646
2026
Q1 		$1.64M Buy
+40,745
New +$878K ﹤0.01% 1333

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Global Advisers's APLS Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 40,745 shares — an estimated $1.64M sold.

Vanguard Global Advisers first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $1.64M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 40,745 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.64M.
  • Vanguard Global Advisers first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Apellis Pharmaceuticals position peaked at $1.64M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.